Researchers have identified how low-dose ketamine alleviates depression by selectively targeting specific NMDA receptors in the brain. Unlike high-dose anesthetic effects, low-dose ketamine binds to lateral grooves on NMDA receptors, enhancing excitatory transmission and long-term synaptic changes.

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment-resistant depression, offering a powerful alternative to traditional treatments. Researchers applied medical criteria to a national pool of patients and found that over half might be eligible for psilocybin therapy, pending FDA approval. If approved, this therapy could significantly impact public health policies, insurance frameworks, and economic costs by reducing reliance on long-term antidepressant prescriptions.